PRT2527

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
274 patients (estimated)
Sponsors
Prelude Therapeutics
Collaborators
BeiGene
Tags
Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1989
NCT Identifier
NCT05665530

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.